Stem Cell Therapeutics Corp. Announces Completion of Enrollment in Key Modified REGENESIS Phase IIb Stroke Trial
March 31 2010 - 5:00AM
Marketwired
Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE:
SSS) announced today that it closed patient enrollment of the
modified Phase IIb stroke trial on March 31st, 2010 and will
analyze the data as they become available. Using a modified
statistical approach the Company will analyze its trial data using
the 96 patients that were enrolled.
Dr. Alan Moore, President and CEO, commented as follows:
"The modified REGENESIS-LED Phase IIb stroke trial enrolled 96
patients in six months which is a tremendous achievement. Despite
our best recruitment efforts, however, we have not recruited any
additional North America patients. The last patient in the trial
was recruited at the end of January 2010. Using an alternate method
of data analysis, with a proven track record (used in one of t-PA's
pivotal phase III studies) will allow us to achieve our endpoint
with fewer patients while staying on track with our previously
reported time-line. We look forward to receiving the results of
this clinical trial for the treatment of stroke patients with
NTx®-265."
With the modified Phase IIb stroke trial closed, SCT anticipates
to complete patient 90 day endpoint assessments by the end of April
2010 with data analysis to follow soon after.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a public biotechnology company (TSX VENTURE: SSS) focused on the
development and commercialization of drug-based therapies to treat
central nervous system diseases. SCT is a leader in the development
of therapies that utilize drugs to stimulate a patient's own
resident stem cells. The Company's programs aim to repair brain and
nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual
property supports the potential expansion into future clinical
programs in numerous neurological diseases such as traumatic brain
injury, multiple sclerosis, Huntington's disease, Alzheimer's
disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO 403-245-5495 ext.224 amoore@stemcellthera.com Stem Cell
Therapeutics Corp. Angelika Goncalves DaSilva Operations Manager
403-245-5495 ext. 221 adasilva@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024